Gene Therapy Market Size, Share, Leading Players and Demand Forecast to 2030

The global gene therapy market attained a revenue of $3,407.5 million in 2019 and is predicted to exhibit a 31.1% CAGR during the forecast period (2020–2030). The market is being driven by the rising research & development (R&D), increasing number of clinical trials that have shown positive results, and growing prevalence of chronic diseases. In terms of vector type, the market is divided into non-viral, viral, and other.

Out of these, the viral division is expected to account for the largest share of the gene therapy market by 2030, which is due to the fact that vectors show higher genomic incorporation levels and expression during clinical trials. In addition to this, these vectors are more efficient as compared to non-viral vectors. On the basis of type, the market is categorized into ex vivo and in vivo, between which, the in vivo category held the larger revenue share of the market during the historical period (2014–2019).

The in vivo technique is much less complicated than the ex vivo technique, where the cells need to be taken out of the body first and then need to be put back inside. Owing to this, in vivo technique is preferred more. In addition to this, the in vivo technique makes sure that the functioning of the host cell is not compromises, thereby leading to its increasing adoption.

Browse full report at: https://www.psmarketresearch.com/market-analysis/gene-therapy-market

Some other key companies operating in the gene therapy market are Spark Therapeutics Inc., bluebird bio Inc., Amgen Inc., Thermo Fisher Scientific Inc., Orchard Therapeutics plc, Pfizer Inc., REGENXBIO Inc., Novartis AG, Applied Genetic Technologies Corporation, and Adverum Biotechnologies Inc.